title: Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol.
authors.affiliation: Canadian HIV Trials Network, Pacific Region, Vancouver, British Columbia, Canada.
authors.forename: Lena
authors.initials: L
authors.lastname: Normén
authors.forename: Jiri
authors.initials: J
authors.lastname: Frohlich
authors.forename: Julio
authors.initials: J
authors.lastname: Montaner
authors.forename: Marianne
authors.initials: M
authors.lastname: Harris
authors.forename: Tom
authors.initials: T
authors.lastname: Elliott
authors.forename: Greg
authors.initials: G
authors.lastname: Bondy
mesh_terms: D008076:Cholesterol, HDL / Q000097:blood* / Q000187:drug effects; D048909:Diabetes Complications / Q000097:blood / Q000188:drug therapy; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy*; D005260:Female; D011345:Fenofibrate / Q000627:therapeutic use*; D006679:HIV Seropositivity / Q000097:blood; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*
chemical_list: D008076:Cholesterol, HDL; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D008055:Lipids; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D011345:Fenofibrate